

# SA Best World S\$1.41 - BUY

Horng Han Low

horng.han.low@clsa.com +65 6416 7847

Jesalyn Wong +65 6416 7810

#### 13 January 2017

#### Singapore Consumer

Priced on 12 January 2017 STI @ 2,993.0

**12M hi/lo** S\$1.64/0.22

12M price target	S\$2.50
±% potential	+78%
Shares in issue	275.2m
Free float (est.)	45.0%
Market cap	US\$272m
<b>3M average daily</b>	<b>volume</b>
S\$2.2m	(US\$1.5m)

Major shareholders
--------------------

D2 Investments Pte Ltd 35.0%

#### Stock performance (%)



www.clsa.com

# Poised for the big leap

#### Well-established track record not fully appreciated

Best World (BW) is a direct-selling company that has built a credible track record. Focusing on the premium skin care, it is well established outside of Singapore, and thus, the investment merits are not fully appreciated. BW's ability to succeed in highly competitive markets like Taiwan and China is a testimony of management capabilities. Despite the share-price rally (480% over the past one year), the stock remains undervalued vs regional peers. Fundamentals are underpinned by 27% EPS Cagr over FY16-18CL and strong free cashflow and backed by ~40% net cash equity. We initiate coverage with BUY and S\$2.50 target price.

#### Track record not fully appreciated

Unlike many direct-selling firms, BW does not require members to make bulk purchase, thus revenue is not inflated. This minimises risks of inventory buildup. Importantly, BW has successfully built its product positioning in the premium skincare segment. The success is evident through the strong revenue growth, as the product, coupled with successful marketing strategies, helps penetrate markets in Taiwan and China. The business model is scalable, enjoys high operating margins, and is consistently free cashflow positive.

#### Exponential growth in Taiwan but will be eclipsed by China

BW's ability to succeed in Taiwan, a highly competitive market, is a litmus test of management capabilities. We project sales to grow sevenfold over five years to reach S\$107m in 2016. Growth looks set to continue, as we expect 20-30% YoY sales growth in 2017-18. However, China will be the game changer. In Nov-16, BW was awarded a direct-selling licence by the Chinese government. This endorsement can significantly propel China sales (33% of sales) and overtake Taiwan (54% of sales) in five years.

#### **Delivering on China**

BW has already built certain scale with a network of beauty salons as distributors. The licence enables BW to gain credibility and differentiate its products. BW can succeed in China, as the market has similar dynamics as Taiwan - a receptive consumer base, utilising online marketing platform and product positioning catering to a discerning group. Marketing events held in China have seen turnouts increasing twofold post the licence award.

#### Strong earnings growth in 2017-18CL

BW trades at a large discount to comparables despite enjoying superior earnings, dividend yield and ROE. Our target at S\$2.50 is based on ~18x 2017CL PE is based on a 30% discount to peer group PEG.

#### **Financials**

Year to 31 December	14A	15A	16CL	17CL	18CL
Revenue (S\$m)	75	102	198	256	312
Net profit (S\$m)	4	8	31	39	49
Core EPS (S¢)	1.9	3.9	11.2	14.1	18.0
Core EPS growth (% YoY)	388.0	105.7	189.0	26.8	27.0
DPS (S¢)	0.0	2.0	4.7	6.0	7.5
EV/Ebitda (x)	26.8	13.6	7.6	5.8	4.3
PE (x)	74.9	36.4	12.6	9.9	7.8
PB (x)	5.4	4.9	4.7	3.7	2.9
ROE (%)	7.7	14.2	42.3	42.0	41.8
Dividend yield (%)	0.0	1.4	3.3	4.3	5.3
Net cash/equity (%)	63.4	76.2	40.0	34.1	44.6

**Initiating covera** 

Find CLSA research on Bloomberg, Thomson Reuters, Factset and CapitaIIQ - and profit from our evalu@tor proprietary database at clsa.com For important disclosures please refer to page 18.




Investment merits of Best World are not fully appreciated	<b>Established track record</b> Best World (BW) is a good quality and well-managed direct-selling company. Focusing on premium skin care, it first established itself outside of Singapore, and thus, the investment merits are not fully appreciated.
Members are not required to make bulk purchase to join its network, thus revenue is not grossly inflated	Since listing in 2004, the firm has built a credible track record. Unlike the practice of many direct-selling firms, distributors of BW are not required to commit large purchases – as membership fees – to join its network or distribute its products. At the same time, it has successfully expanded in Taiwan and China, markets that offer significant growth potential.
	BW primarily targets users of its products, hoping to convert them as sales agents eventually. The practice of not requiring to purchase huge inventory is important, as it implies there is no "inventory stuffing" in the distribution channel where revenue can be grossly inflated as a result. This enables investors to keep track of inventory build-up, which could suggest potential slowdown in sales.
	However, the exception to this practice is in China, where distributors need to purchase RMB20,000 worth of products. This is equivalent to five sets of skincare products. This is practised only in China to facilitate logistical efficiency given the geographical expanse of the country.
Obtaining the coveted direct-selling licence in China is a testimony to the firm's credibility	<b>Obtaining the coveted direct-selling licence in China</b> BW was awarded the much-coveted direct-selling licence by the Chinese government in Nov-16, due to its track record and quality products. This is a testimony of the firm's credibility and product efficacy, in our view. Since 2006, approximately 80 licences have been awarded in China. The reputable

BW is the only Singapore name to receive the award. This can enable the firm to capitalise on rapid industry growth. Despite economic headwinds, skin-care products is one of the fastest-growing segments in China today. According to McKinsey, sales of premium skincare products, for instance, rose by more than 20% a year in the past decade while the industry average was 10%.

Best World – Operating margin vs net profit

Beijing-based medical hall Tong Ren Tang was awarded about the same time



as BW.

#### Effective and low-cost distribution model Figure 2

Figure 1



25%

20%

15%

10%

5%

0%

2018CL

2015

2016CL

2017CL


2014


Source: CLSA, Company



Scalable business model and less subjected to business overhead


Enjoys consistently high gross margin but operating margin can be volatile due to effects of operating leverage As a direct-selling company, the business model is scalable, particularly as the company increases the distributorship network. Compared with traditional retailers, BW has no retail outlets and therefore is not subjected to volatility in rental costs, marketing expenses or high overheads. BW outsources manufacturing to third parties, removing capex needs. At the same time, distributors are not paid salaries but work on commissions. This enables it to deliver consistently high gross margin in excess of 70%. Operating margin, however, is much more volatile due to effects of operating leverage.





Source: CLSA, Company; Note: \* Payout ratio was 184% in 2010, 0% in 2011 and 136% in 2013 due to low net profit registered in these three years

As a direct distributor, BW's commission-based scheme is an effective tool to generate sales. As the income of distributors depends on his/her rank and the revenue generated by his/her team, distributors are self-motivated to finesse their marketing techniques and expand their network of sellers. Nevertheless, we believe the numbers delivered are telling of their track record. Since listing in 2004, when the firm raised ~S\$5m, it paid out ~\$36m dividends and has not raised capital since. BW is net cash and consistently generates positive free cashflow.



Net cash equity will stabilise ~40%



Taiwan and China contributes more than 80% of revenue

BW did not adopt an aggressive pricing strategy during its growth phase Taiwan and China are key markets

Taiwan and China are BW's key markets, accounting for  $\sim$ 54% and  $\sim$ 33% of sales respectively. Although both markets are extremely competitive, BW has seen success in its market penetration. We opine the firm is still in the early stages of growth.

During its growth phase, it is important to note that Best World did not adopt an aggressive pricing strategy. The focus was on expanding the distribution network, ensure product quality and cultivate a premium brand. The key product is Dr's Secret range of skincare products. A set costs S\$800 in Singapore, RMB4,397 in China and NT\$18,100 in Taiwan.

Targets the mid- to highend market

Best World – Range of premium skin care products



Source: CLSA, company

Figure 6


#### Exponential growth in Taiwan

Although BW began operations as early as 2008, it was only in 2013 that marketing efforts in the Taiwan market began to intensify. Thus, BW is a relatively late entrant compared with major brands such as Nu Skin and Amway. Nonetheless, Taiwan has grown to become a key contributor, with sales accounting for 60% of group sales in 9M2016. Despite Taiwan's anaemic economic growth in recent years, BW achieved strong product penetration.

Revenue is projected to grow more than sevenfold since 2010 from S\$16m to S\$107m (58% of sales) by the end of 2016. The strongest revenue growth was registered in 2015 when Taiwan GDP growth fell from 5.7% to 3.7%. Management believed this was a result of BW's training and marketing efforts. Within the direct-selling industry, management estimates BW should be ranked #15 in Taiwan in terms of revenue, and thus, sales are yet to saturate. Going forward, we project sales growth of 20-30% YoY in 2017-18.

BW is a late entrant in Taiwan but succeeded in expanding its distributorship








Figure 9



#### Figure 10



Source: Republic of China (Taiwan) National Statisticsc

#### **Receptive consumers set the stage**

A receptive consumer base sets the stage for BW to maintain its strong performance. In Taiwan, the biggest direct-selling category is consumer healthcare (40%), followed by beauty and personal care (13%).



Direct selling is well accepted in Taiwan, but not Singapore According to Euromonitor, "Direct selling is a well-developed and wellrecognized channel in Taiwan...Direct selling players continued to grow their customer bases, with new young consumers being the target to this expansion. Overall, direct selling products are perceived by Taiwanese consumers as being of good quality."

This makes it easier for BW to build a strong consumer base. This contrasts with Singapore where purchase of skincare is usually over the counter.

Management avoided head-on competition with established names by focusing on Taichung instead of Taipei Taiwan's direct-selling market is highly fragmented and dominated by international players such as Amway, Melaleuca and Nu Skin. Since BW is a late entrant in Taiwan, management avoided head-on competition by launching its first regional centre in Taichung instead of Taipei. Marketing efforts were largely concentrated in Taichung to build reputation and distributor network. With the success, it began to roll out in other cities.

Figure 11 With a "Young Entrepreneur"



Source: CLSA

A litmus test for direct selling is ability to expand distributorship

Figure 12



Source: CLSA

### Engaging the right distributors

A litmus test for a direct-selling company to succeed is the ability to expand its distributorship. One of the initiatives adopted was to recruit young and business-minded consumers as their "Young Entrepreneurs".

Younger distributors are also more adept in using online platforms to promote the products. Currently, 70% of its distributors are under the age of 35 in Taiwan. Since 2013, BW has launched three training centres across Taiwan. The opening of the centres provides a venue for recruitment, training and marketing initiatives.

These "Young Entrepreneurs" are generally beauticians or owners of beauty/hair & nail/spa salons. Many are certified beauty professionals, and thus, they have a ready customer base to reach out to. The distributors also use Facebook/LINE chat/WeChat to share their BW experience: "before-andafter" skin photos, starting a business with BW, etc. This a common practice but is also the most-effective marketing tool among multi-level marketing (MLM) players.



#### Capitalising on the momentum in China

On 17 November 2016, BW officially obtained its direct-selling licence from China's Ministry of Commerce (MOFCOM). This is significant, as the Chinese government has always taken a cautious approach towards direct-selling companies.

Direct-selling award reinforces credibility of the firm and its products The award of the licence can be a game changer for BW and help expand market share. The licence enables the firm to gain credibility, differentiate its products, and importantly attract more distributors. BW has been working to expand its distribution network in China over the past few years in anticipation of securing the licence; therefore, it is now poised to further capitalise on its network with this approval.

Prior to the direct-selling licence, BW has already built certain scale in China via the export model. Under the export model, BW relies on several export agents to distribute its products to a network of beauty salons, nail & hair salons and spas. It has a strong presence in tier-2 or tier-3 cities such as Changsha, Wenzhou, Harbin and Zhongshan. They achieved consistent growth from 2012 to 2015, followed by a sharp increase in 9M2016. Revenue in 9M2016 exceeded total export revenue in 2015, with 704% QoQ growth in 1Q2016, 615% in 2Q2016 and 366% in 3Q2016.

Post the announcement of BW's licence award in Nov-2016, BW's quarterly marketing events attracted a turnout of 1,500 participants in Dec-2016, higher than the usual 600-900 turnout per quarter. Compared with 2015, the average turnout per quarter ranges between 300-700. The number of participants during such events reveals the potential of the distributorship across China. This is a signal of its product acceptance. As a result, management has plans to raise prices in China by 7% in 2017.





# BW plans to convert export model to direct-

export model to directselling model in several phases

Turnout during marketing events has risen threefold since award of direct selling licence





Source: CLSA, company

Figure 15



Source: CLSA, company


The inclusion of more cities under the directselling licence will take ~6 months

Exponential growth achieved for the Chinese

market

Market dynamics for direct selling in China are similar to Taiwan. It is rampant with distributors using online platforms such as WeChat to advertise their products. Distributors range from consumers to beauty salon owners, who also distribute these products to their salon customers.

With the licence, BW can easily expand its geographical and product coverage and convert from the current export model to direct selling. By 2017, BW hopes to start the application for cities where it has a presence such as Changsha, Wenzhou, Harbin, and Zhongshan.




Source: CLSA, Company

#### China market offers significant potential

China market potential is much larger than Taiwan

China is the second-largest direct-selling market in the world. According to Euromonitor, the direct-selling market in China has achieved 10% growth in 2015, reaching US\$19.2bn in retail value. It projected the market will continue to expand at 6% Cagr. As a backdrop, McKinsey projects household income to rise, with the affluent household income group growing from 11% in 2012 to 25% in 2022.



Source: CLSA, Euromonitor

Personal beauty care is one of the top-selling categories in China

**BW's product positioning** can meet the demand of discerning consumers The top-two direct selling categories in China are: 1) consumer healthcare; 2) beauty and personal care. These two categories are projected by Euromonitor expected to grow at 10% per annum, higher than the growth of other directselling categories.

BW product positioning is well poised to meet the demand of increasingly discerning consumers at the mid to high end level. Management plans to raise prices in China in 2017.

#### Figure 21

prices					
Cleanser (RMB)	Cleanser (RMB/ml)	Moisturizer (RMB)	Moisturizer (RMB/ml)		Essence (RMB/ml)
400	3.39	568	18.93	998	33.27
265	8.83	400	16.00	1500	50.00
410	4.10	860	17.20	850	28.33
310	2.07	780	15.60	590	19.67
	Cleanser (RMB) 400 265 410	Cleanser (RMB) Cleanser (RMB/ml)   400 3.39   265 8.83   410 4.10	(RMB)(RMB/ml)(RMB)4003.395682658.834004104.10860	Cleanser (RMB) Cleanser (RMB/ml) Moisturizer (RMB) Moisturizer (RMB/ml)   400 3.39 568 18.93   265 8.83 400 16.00   410 4.10 860 17.20	Cleanser (RMB) Cleanser (RMB/ml) Moisturizer (RMB) Moisturizer (RMB) Essence (RMB/ml)   400 3.39 568 18.93 998   265 8.83 400 16.00 1500   410 4.10 860 17.20 850

China pricing for se	lect Dr's	Secret prod	ucts			
	2012	2013	2014	2015	2016	2017
T1 Cleanser (118ml)	¥380	¥390	¥392	¥400	¥400	¥428
T2 Toner (118ml)	¥380	¥390	¥392	¥400	¥400	¥428
3 Moisturizer (30ml)	¥530	¥550	¥556	¥568	¥568	¥608
C15 Essence (15ml)	¥640	¥660	¥666	¥678	¥678	¥725
T9 Serum (30ml)	¥380	¥395	¥398	¥406	¥406	¥434

Source: CLSA, Company

The inclusion of more cities in the direct-selling licence will take ~ 6-12 months

coverage. Approval for subsequent applications will be much faster: less than 6 months for simultaneous applications and up to 5 provinces. By 2017, BW hopes to start the application for cities where it has a presence such as Changsha, Wenzhou, Harbin, and Zhongshan.

Inclusion of other products under the licence will take a few weeks The inclusion of other products under the direct-selling licence is expected to take approximately a few months, given these products have already passed extensive tests (animal test, human clinical trials, etc) and obtained approval from China Food and Drug Administration.

With the licence, BW can easily expand its geographical and product

Figure 23									
Applicat	Application plans for broader coverage under direct-selling licence								
Time	Geography	Products	Remarks						
2017	Cities where BW has a strong presence, such as Changsha, Wenzhou, Harbin, zhongshan etc, in at least 5 provinces	All products	These products will be manufactured by BW's current third-party manufacturers						
2018 onwards	Other major cities and provinces in China	All products	Products will be manufactured by third-party manufacturers until the approval of skincare products, which will be manufactured by BW's Singapore plant						

Source: CLSA, Company



Strong financial projections We project BW can deliver net profit Cagr of 27% over 2016-18. This Taiwan and China are key to BW's profit growth translates to net profit of S\$31m in 2016 and S\$39m in 2017. Growth in momentum profit is underpinned largely by Taiwan and China. Both markets are critical to fundamental outlook, as the firm continues to expand market penetration. Over the next three years, we expect operating margins to stay above 20% (vs 2-16% in 2013-15) as it enjoys the effects of operating leverage due to strong topline growth. In 2017, operating margin could contract slightly by  $\sim 1\%$  due to increase in operating expenses, as BW sets up service centres and marketing events to promote the Dr's Secret skincare range. Nonetheless, strong revenue growth would still enable the firm to deliver 27% CAGR profit growth over 2016-18. Three critical success factors underpin our optimism: We project operating Successfully built the right product positioning that caters to a discerning margin to rise above 20% group of consumers. This is evident via product sales growth in Taiwan for 2016-18 and project positive free cashflow and China. Importantly, the success in its marketing efforts for Dr's Secret range of premium skincare was not driven by a strategy of price cuts. Prices have increased steadily over the past few years instead. □ Successful rollout of distribution centres in China. BW has already built certain scale with a network of beauty salons as distributors. Their market presence is especially strong in Changsa. Award of direct-selling licence by China Ministry of Commerce. This is a testimony of product quality and significantly enhances credibility of the brand. Well-heeled consumers in China are willing to pay premium prices.

#### Figure 24

<b>Global Valuation Co</b>	mparison											
Company	Ticker	Price	Market Cap	PE (x	) EV/	Ebitda	EPS G	Growth (%)	F	РВ (Х)	ROE (%)	Div Yield (%)
			(US\$m)	2017 201	8 2017	2018	2017	2018	2017	2018	2017	2017
HK/China												
XIANGXUE PHARM-A	300147 CH	12.9	1,238	36.9 30.	1 31.1	25.1	66.7	22.9	2.4	2.2	6.5	-
BAIYUNSHAN PH-H	874 HK	19.2	5,390	16.4 15.	3 14.8	13.2	3.3	7.2	1.8	1.8	13.2	1.7
Taiwan												
GRAPE KING BIO	1707 TT	171.5	724	14.2 12.	3 7.8	6.6	22.6	15.3	3.7	3.1	29.1	4.5
CHLITINA HOLDING	4137 TT	149.5	375	17.3 13.	7 8.9	7.0			3.1	2.8	17.5	4.7
Malaysia												
HAI-O ENTERPRISE	HAIO MK	4.15	179	16.0 14.	1 10.0	9.0	39.0	13.5	3.0	2.8	18.9	4.3
AMWAY MALAYSIA H	AMW MK	7.50	276	18.8 15.	5 11.3	8.6	19.4	20.8	5.7	5.0	20.4	4.5
United States												
NU SKIN ENTERP-A	NUS US	49.6	2,703	15.5 14.	2 7.4	7.1	8.8	9.6	5.2	4.7	21.3	3.0
HERBALIFE LTD	HLF US	49.7	4,628	10.3 9.	9 7.1	6.7			-	-	-	-
USANA HEALTH SCI	USNA US	61.3	1,496	13.7 11.	1 7.8	NA	9.9	23.3	8.1	6.6	30.3	-
Singapore												
BEST WORLD INTL	BEST SP	1.40	271	9.9 7.	8 5.8	4.3	27.3	21.4	3.7	2.9	42.0	4.3



Despite aggressive growth projections, we do not expect working capital to intensify, thus we project positive free cashflow in 2017-18. Capex requirement for BW is for the set-up of a manufacturing plant in Singapore by end-2017. The objective of setting up the plant is to reduce the long lead times from third-party OEMs which could stretch up to 6 months and will cost the firm S\$15m. More than S\$10m will be committed in 2016; therefore, capex in 2017-18 will reduce significanly.

#### \$2.50 target price

We expect net cash position of \$32m in 2017. With a healthy balance sheet and cashflow, dividend payout ratio can comfortably be maintained at 40% or higher. We value Best World at ~18x 2017CL PE multiple. This is based on a PEG of 0.65x using 2016-2018CL EPS Cagr of 27%. This translates to ~18x PE and a target price of S\$2.50. The PEG of ~0.65x is based on a ~30% discount to the PEG of the peer group average of ~0.9x. On PE multiple, we expect the stock to trade on par with regional peers.

Given the stronger growth rate, we believe this fair value multiple is not aggressive. Other comparables are trading at an average of  $\sim$ 19x 2017 PE multiple but offer lower ROE.

We value BW at 0.7x PEG, translates to 19x PE multiple; this is on par with global peers but BW enjoys superior financials



BW has been listed since 2004

### Company background

Founded in 1990, Best World International Ltd (BW) is a Singapore-based direct-selling company that specialises in the development, manufacturing and distribution of premium skincare, personal care, nutritional and wellness products. In 2004, it was listed on the SGX and remains the only direct-selling company listed in Singapore. Today, it has become a regional player with 429,000 independent distributors and members in 12 markets across China, South East Asia, and the Middle East.

#### Management

Key management members are Dr Dora Hoan (CEO), Dr Doreen Tan (President) and Huang Ban Chin (Group COO). Each of them has been with the firm for more than 20 years. Collectively, they own 55% stake in the company. The Group Financial Controller is Ms Koh Hui, who has been with BW for the past 13 years.

Figure 25									
Key management equity stake (%)									
Name	Prior to IPO	Post IPO	Current stake	Remarks					
Dr Dora Hoan	34	10.3	6	Vendor share sale in 2007					
Dr Doreen Tan	34	10.3	6	Vendor share sale in 2007					
Huang Ban Chin	4	3	4.5	NM					
D2 Investment	nil	36.4	37.7	D2 Investment is jointly owned by Dr Dora and Dr Doreen					

Source: Company

Figure 26

Details - Manager	ment and Board of Directo	ors	
Name	Rank	Service length	Other directorships and commitments
Dr Dora Hoan Beng Mui	Co Chairman/Group CEO	26 years	Chairman, Direct Selling Association, Singapore, Chairman, World Learner Exchange Program, Vice chairman, Radin Mas CCC
Dr Doreen Tan Nee	Moi	26 years	Corporate Council Board Member, Asean Alliance of Health Supplements Associations Vice chairman, World Learner Exchange Program Patron, Pasir Ris CCC
Huang Ban Chin	Executive Director and Chief Operating Officer	22 years	None
Mr Lee Sen Choon	Chairman of Audit Committee, Lead Indpendent Director	12 years Bo	ard of director in Hor Kew Corp and Soon Lian Holdings, Chairman, Hwa Chong Institution Board of Directors
Mr Ravindran Ramasamy	Chairman of Nominating Committee	13 years	Director at Serial System Practicing Partner at Colin Ng & Partners LLP
Mr Chan Soo Sen	Chairman of Remuneration Committee	NA	Director at Breadtalk, Midas and Cogent Previously served as Minister of State, Various Ministries in Singapore and formerly CEO Sino-Singapore Suzhou Industrial Park

Source: Company

In 9M16, Taiwan accounted for 60% of revenue, followed by China at 30%


#### Segmental breakdown

The company's business can be segmented into three parts, with direct selling contributing ~69% of 9M2016 revenue. The export segment which captures retail sales from China contributed ~28% in 9M2016. The remaining overall sales comes from the manufacturing/wholesale segment, which captures revenue realised through the wholesale channel in China only.



As of 9M2016, Taiwan is the company's biggest revenue earner at 60%, and China is second at 30%. Singapore and Indonesia come next at 3.5% and 2.8% respectively, while the rest of the markets total  $\sim$ 4% of overall revenue.

In terms of product line, the biggest revenue generator for the company is its skincare products. This was followed by nutrition and wellness products at 10.6% and health supplements of 9.8%.



Source: CLSA, Company

The company has a total of 8 brands ranging from skincare to health supplements and Dr's Secret is its best-selling product. The Aurigen brand products were originally not developed by BW, but developed and manufactured by Zhejiang SolidGold Pharmaceutical Co Ltd in Hangzhou, China.

	Figure 30		
Dr's Secret is the best-	Company products at a	glance	
selling brand	Product category	Brands	Remarks
	Skincare		
		Dr's Secret	Best-selling skincare brand
		Miraglo	Patented ultrafine microfibre products for skincare
		Aestier	Repair and treatment range under Dr's Secret
	Health supplements		
		Avance	Focus on beauty and skincare, for digestive health, circulatory health, natural resistance, rejuvenation, outer radiance and oral care
		Aurigen	Products developed by Zhejiang SolidGold Pharmaceutical Co Ltd before acquisition. Focus on general health.
	Weight managements		
		Optrimax	
	Others		
		Pentalab	Body and foot care
		UberAir	Air refresher
	Source: CLSA Company		

Source: CLSA, Company

All BW products were manufactured from thirdparty manufacturers with GMP licence In terms of product supply, the company employs third-party manufacturers who are awarded with the Good Manufacturing Practice (GMP) licence from the Singapore Health Sciences Authority to manufacture its products. A GMP licence is granted when the manufacturing facility has been audited and found to demonstrate satisfactory compliance with the required GMP standard.



BW owns a manufacturing plant in China, producing non-core health supplements to be sold in drug stores

BW acquired a manufacturing plant in Singapore to manufacture Dr's Secret, in anticipation of strong demand from China and Taiwan In 2014, BW completed the acquisition of a Chinese health supplements manufacturing plant, Zhejiang SolidGold Pharmaceutical Co Ltd in Hangzhou, China. The acquisition met one of the Chinese government's requirements for the application of a direct selling licence. Currently, this plant is manufacturing BW's health supplements brand, Aurigen, which is sold to drug stores across China.

BW is currently constructing a manufacturing plant in Singapore, which is expected to be in full operation in 3Q2017. Management guided that the plant would be fully automated to manufacture its best-selling skincare brand, Dr's Secret. This should help BW with greater control over its product supply, particularly in anticipation of greater demand from China and Taiwan.

Currently, the revenue generated from the China market comprises two parts: 1) Export and 2) Wholesale. In November, BW obtained its first direct-selling licence in China, but sales activities through the direct-selling channel have yet to kick in.

Figure 31								
Current business model in China								
Business segment	Geography	Products	Manufacturer	Remarks				
Export	Strong presence in cities such as Changsha, Wenzhou, Harbin, Zhongshan, etc, across at least 5 provinces	All products	Third-party manufacturers around the world	All products are registered and can be sold across China				
Wholesale	31 provinces in China	All Aurigen brand health supplements	Pharmaceutical Co	Aurigen is being sold to agents who will then distribute to drug stores across China				

Source: CLSA, Company

Figure 32

Earnings and balance-sheet risk scores (lower the better)

	Score	Comments
Earnings-quality flags		
Capex indiscipline		
Cash burn	0	
Rising non-core or intangibles	0	
Rising working capital	0	
Poor cash conversion	0	
Earnings-quality risk score (EQRS)	0/4	Working capital well managed; Operating margins can improve
Balance-sheet-quality flags		
Cash burn	0	
Excessive leverage	0	
Frequent fundraising	0	
Liquidity concerns	0	
Operational stress	0	
Balance-sheet-quality risk score (BQRS)		Not capital intensive
Source: CLSA		

#### Valuation details

We value Best World at ~18x 2017CL PE multiple. This is based on a PEG of 0.65x using 2016-2018 EPS Cagr of 27%. This translates to a multiple ~18x PE and a target price of S\$2.50. The PEG of ~0.65x is based on a ~30% discount to the PEG of the peer group average of ~0.9x. On PE multiple, we expect the stock to trade on par with regional peers. Given the stronger growth rate, we believe this fair value multiple is not aggressive. Other comparables are trading at an average of ~19x 2017 PE multiple but offer lower ROE and growth potential.

#### **Investment risks**

1) Price war among direct-selling companies will impact margin, 2) Government regulations that could impede growth for direct-selling firms in key markets like Taiwan and China, and 3) inventory build-up should sales for new distribution centres in China disappoint.

### **Company outline**

#### The business

Best World International Ltd is a Singaporebased direct-selling company specialising in the development, manufacturing and distribution of premium skincare, personal care, nutritional and wellness products. Today, it is a regional player in 12 markets across China, South East Asia, and the Middle East.

**Competition & market franchise** The company competes with local counterparts within Asia. There are three main business segments for the company; (i) direct selling, (ii) export and (iii) manufacturing/wholesale. Direct selling segment mainly comprises sales to customers through direct selling channels in Singapore, Malaysia, Indonesia, Thailand, Taiwan, Hong Kong, Vietnam, Philippines, Korea, Australia and United Arab Emirates ("UAE"); Export sales segment comprises sales to retail customers at export retail price through retailers in the People's Republic of China and Mvanmar: Manufacturing/wholesale segment comprises sales to customers through wholesale channel in People's Republic of China. Geographically, BEST's largest exposure is Taiwan which contributes close to 60% of its revenues.





## **Summary financials**

	Year to 31 December	2014A	2015A	2016CL	2017CL	2018C		
	Summary P&L forecast (S\$r							
	Revenue	75	102	198	256	31		
	Op Ebitda	10	19	47	60	7		
	Op Ebit	7	19	47	55	6		
xpect net profit to	Interest income	0	0	44	0	0		
achieve 27% Cagr								
	Interest expense	0	0	0	0			
	Other items	(2)	0	(2)	(2)	(2		
	Profit before tax	6	17	42	54	6		
	Taxation	(2)	(8)	(11)	(13)	(17		
	Minorities/Pref divs	0	(1)	(1)	(1)	(2		
	Net profit	4	8	31	39	4		
	Summary cashflow forecast (S\$m)							
	-		10					
	Operating profit	7	16	44	55	6		
	Operating adjustments	(2)	1	(2)	(2)	()		
	Depreciation/amortisation	3	3	3	5			
	Working capital changes	4	0	(25)	(12)	(		
	Net interest/taxes/other	(1)	(3)	(11)	(14)	(1		
Mining	Net operating cashflow	11	17	9	33	5		
Minimal capex	Capital expenditure	-	-	-	-			
requirements	Free cashflow	11	17	9	33	5		
	Acq/inv/disposals	0	(3)	(13)	(10)	(		
	Int, invt & associate div	(7)	0	(13)	(10)	(		
	Net investing cashflow	(7)		(13)	(10)	(!		
	Increase in loans		(3)			(		
		2	(6)	2	(6)	(2		
	Dividends	(1)	(2)	(13)	(17)	(2		
	Net equity raised/other	2	(5)	0	0			
	Net financing cashflow	3	(13)	(10)	(23)	(2		
	Incr/(decr) in net cash	8	2	(14)	1	2		
	Exch rate movements	2	6	6	6			
	Opening cash	32	39	41	27	2		
	Closing cash	41	47	33	34	5		
		(0+ )						
mains in net cash	Summary balance sheet fore		4 7	22	24			
position	Cash & equivalents	41	47	33	34	5		
	Debtors	9	11	22	32	3		
	Inventories	8	12	22	31	3		
	Other current assets	9	7	7	7			
	Fixed assets	8	7	17	22			
	Intangible assets	8	7	6	5			
	Other term assets	2	4	4	4			
	Total assets	84	94	111	135	10		
	Short-term debt	5	-	-	-			
	Creditors	19	25	20	28			
	Other current liabs	2	6	6	6			
	Long-term debt/CBs	1	0	0	0			
	Provisions/other LT liabs	2	2	2	2			
	Minorities/other equity	(1)	(2)	1	(5)	(		
	Shareholder funds	56	64	81	104	1		
h ROE, operating	Total liabs & equity	84	94	111	135	16		
margins yet	Ratio analysis							
	Revenue growth (% YoY)	83.2	35.1	94.4	29.6	21		
						21		
	Ebitda growth (% YoY)	352.3	89.7	143.8	29.4	26		
	Ebitda margin (%)	13.4	18.8	23.5	23.5	24		
	Net profit margin (%)	5.4	8.4	15.5	15.2	15		
	Dividend payout (%)	0.0	51.8	42.1	42.4	41		
	Effective tax rate (%)	28.0	45.3	25.0	25.0	25		
	Ebitda/net int exp (x)	-	-	-	-			
	Net debt/equity (%)	(63.4)	(76.2)	(40.0)	(34.1)	(44.		
	ROE (%)	7.7	14.2	42.3	42.0	41		
	ROIC (%)	25.9	45.7	95.3	69.1	73		
		23.5	+5.7	90.0		13		
	EVA®/IC (%)	14.0	33.7	83.3	57.1	61		





#### **Research subscriptions**

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

#### Companies mentioned

Best World (BEST SP - S\$1.41 - BUY) Amway (N-R) Baiyunshan Pharma (N-R) Breadtalk (N-R) Chlitina (N-R) Cogent (N-R) D2 Investment (N-R) Grape King (N-R) HAI-O ENTERPRISE (N-R) Herbalife (N-R) KINO BIOTECH (N-R) Midas (N-R) Nu Skin (N-R) SAGITTARIUS (N-R) Serial System (N-R) Usana Health (N-R) XIANGXUE (N-R)

#### Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

#### **Important disclosures**

The policy of CLSA (which for the purpose of this disclosure includes subsidiaries of CLSA B.V. and CLSA Americas, LLC ("CLSA Americas")), and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of discloseable position should not be taken as а endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and

Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a preexisting holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLSA Americas/CLST did not receive investment banking/noninvestment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLSA Americas/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLSA Americas/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12month forecast return (including dividends) for the market on which the stock trades.

In the case of US stocks, the recommendation is relative to the expected return for the S&P500 of 10%.

Exceptions may be made depending upon prevailing market conditions. We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLSA Americas only /CLST only Universe:

Overall rating distribution: Buy / Outperform - CLSA: 61.61%; CLSA Americas only: 54.55%; CLST only: 71.62%, Underperform / Sell - CLSA: 38.39%; CLSA Americas only: 45.45%; CLST only: 28.38%, Restricted -CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00%. Data as of 31 December 2016.

Investment banking clients as a % of rating category: Buy / Outperform - CLSA: 3.55%; CLSA Americas only: 0.00%; CLST only: 0.00%, Underperform / Sell - CLSA: 2.85%; CLSA Americas only: 0.00%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00% . Data for 12-month period ending 31 December 2016.

There are no numbers for Hold/Neutral as CLSA/CLSA Americas/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA Americas, Compliance Department, 1301 Avenue of the Americas, 15th Floor, New York, New York 10019-6022; (b) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). © 2017 CLSA Limited, CLSA Americas, and/or CLST.

© 2017 CLSA Limited, CLSA Americas, LLC ("CLSA Americas") and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (www.clsa.com/disclaimer.html.). Neither the publication/communication nor any portion hereof may reprinted, sold, resold, copied, reproduced, be distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA group of companies (excluding CLSA Americas, LLC) ("CLSA"),

CLSA Americas (a broker-dealer registered with the US Securities and Exchange Commission and an affiliate of CLSA) and/or CLST.

CLSA, CLSA Americas and CLST has/have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA, CLSA Americas and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA, CLSA Americas and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA, CLSA Americas and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA, CLSA Americas and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA, CLSA Americas and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion

about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLSA Americas, CLST, their respective affiliates or companies or individuals connected with CLSA/CLSA Americas/CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLSA Americas, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research\_disclosures/. Disclosures therein include the position of CLSA, CLSA Americas and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company covered in this publication/communication.. If investors have anv difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in United Kingdom by CLSA (UK).

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

Singapore: In Singapore, research is issues and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services license holder to deal in securities and an exempt financial adviser, a solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity (including CLSA Americas), CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA/CLSA Americas and "CT" stands for CLST estimates unless otherwise noted in the source.